Company profile

GTN company profile

Bringing a single new drug to the market costs $2.9bn, often delivering an intervention that barely differs from those already in the market. Projections into the future are not promising, with an expected 50% drop in R&D output every nine years. At GTN they are searching the astronomically large space of drug-like molecules with their unique patented technology, Generative Tensorial Networks. Their software combines and builds upon techniques from machine learning and quantum physics to simulate, filter and search for molecules, halving development costs and discovering molecules entirely hidden from view.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
00011-00050 employees
Revenue range
$1K+
Founded
2017-05-17

Headquarters

Headquarters
Newdigate, England, United Kingdom
Postal code
EC1V 9NR
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Seed
Funding rounds
3
Total equity funding
$2.8M
Last funding
Seed / 2018-11-01
Last equity funding
Seed
Investors
6
Lead investors
4
Founders
2
Articles
40

Founders and investors

Founders

Noor ShakerVid Stojevic

Lead investors

Google for StartupsIsomer CapitalOctopus VenturesPentech Ventures

Investors

Entrepreneurs FirstGoogle for StartupsIsomer CapitalOctopus VenturesPentech Ventures

People at this company

Preview only. Contact details are available after you sign in.

Log in to view people and contact details at this company

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Sign in to view shipment history, products, suppliers, and trade lanes for this company.

Log in to view shipment data

Shipment records and coverage can change as the dataset is updated.